Bruno Strigini has been CEO of Novartis Oncology since July 1, 2016. He is a member of the Executive Committee of Novartis.

Mr. Strigini joined Novartis in June 2014 as President of Oncology. Prior to Novartis, he was President of MSD for Europe and Canada (Merck & Co. Inc. in the United States and Canada). He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham, and his roles included President of International Operations, President of Japan and Asia-Pacific, Head of Global Marketing and Business Development, and Managing Director positions.

Mr. Strigini holds a Master of Business Administration from IMD in Switzerland, a Doctorate in Pharmacy from the University of Montpellier in France, and a Master in Microbiology from Heriot-Watt University in the United Kingdom. He is an elected member of the French National Academy of Pharmacy, and in 2014, he was awarded a Doctor Honoris Causa from Universidad Internacional Menendez Pelayo in Spain.